Home LiteratureArticle Details
PMID: 21562580 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Cell-free nucleic acids as biomarkers in cancer patients.

Nature reviews. Cancer ·Vol. 11 ·No. 6 ·2011-06-00 ·Pages 426-37

Schwarzenbach H, Hoon DS, Pantel K

Abstract

DNA, mRNA and microRNA are released and circulate in the blood of cancer patients. Changes in the levels of circulating nucleic acids have been associated with tumour burden and malignant progression. In the past decade a wealth of information indicating the potential use of circulating nucleic acids for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies has emerged. In this Review, we discuss these findings with a specific focus on the clinical utility of cell-free nucleic acids as blood biomarkers.

MeSH Terms
Apoptosis Biomarkers, Tumor/blood DNA/blood DNA, Viral/blood Humans MicroRNAs/blood Mutation Neoplasms/blood,genetics RNA, Messenger/blood
Chemicals
Biomarkers, Tumor DNA, Viral MicroRNAs RNA, Messenger DNA
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Schwarzenbach Heidi
Institute of Tumour Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.
Hoon Dave S B
Pantel Klaus
References (179)
179 references, click to expand
  1. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer.
    Cancer Genet Cytogenet. 2010 Oct 1;202(1):1-10 PMID: 20804913
  2. Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer.
    Ann N Y Acad Sci. 2000 Apr;906:72-82 PMID: 10818600
  3. Differential methylation profile of ovarian cancer in tissues and plasma.
    J Mol Diagn. 2009 Jan;11(1):60-65 PMID: 19074590
  4. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer.
    J Surg Oncol. 2002 Feb;79(2):101-6 PMID: 11815997
  5. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma.
    J Cancer Res Clin Oncol. 2006 Jun;132(6):399-407 PMID: 16502316
  6. Clinical biomarkers in oncology: focus on colorectal cancer.
    Mol Diagn Ther. 2009;13(2):103-14 PMID: 19537845
  7. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
    Clin Cancer Res. 2002 Dec;8(12):3761-6 PMID: 12473587
  8. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients.
    Br J Cancer. 2009 Apr 21;100(8):1277-86 PMID: 19367284
  9. Circulating nucleic acids in plasma and serum. Recent developments.
    Ann N Y Acad Sci. 2008 Aug;1137:1-6 PMID: 18837917
  10. Targeting RAS signalling pathways in cancer therapy.
    Nat Rev Cancer. 2003 Jan;3(1):11-22 PMID: 12509763
  11. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis.
    Cancer Sci. 2010 Oct;101(10):2087-92 PMID: 20624164
  12. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
    PLoS One. 2010 Feb 04;5(2):e9061 PMID: 20140221
  13. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue.
    Histol Histopathol. 2004 Apr;19(2):575-83 PMID: 15024717
  14. Linking DNA methylation and histone modification: patterns and paradigms.
    Nat Rev Genet. 2009 May;10(5):295-304 PMID: 19308066
  15. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors.
    Obstet Gynecol. 2008 Oct;112(4):843-50 PMID: 18827127
  16. Detection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination.
    Chin J Cancer. 2011 Feb;30(2):120-3 PMID: 21272444
  17. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
    Cancer Sci. 2006 Dec;97(12):1366-73 PMID: 17052260
  18. Frequent copresence of methylated DNA and fragmented nucleosomal DNA in plasma of lymphoma patients.
    Clin Chim Acta. 2003 Sep;335(1-2):89-94 PMID: 12927689
  19. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.
    Clin Chem. 2009 Apr;55(4):611-22 PMID: 19246619
  20. Detection and quantification of mutations in the plasma of patients with colorectal tumors.
    Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16368-73 PMID: 16258065
  21. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer.
    Urology. 2002 Dec;60(6):1131-5 PMID: 12475696
  22. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Life Sci. 2010 Jul 17;87(3-4):83-91 PMID: 20470789
  23. Inhibition of mutated, activated BRAF in metastatic melanoma.
    N Engl J Med. 2010 Aug 26;363(9):809-19 PMID: 20818844
  24. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
    Int J Cancer. 2002 Aug 10;100(5):542-8 PMID: 12124803
  25. Multimarker circulating DNA assay for assessing blood of prostate cancer patients.
    Clin Chem. 2009 Mar;55(3):559-67 PMID: 19131636
  26. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
    Oncogene. 2005 Sep 1;24(38):5858-67 PMID: 16007211
  27. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients.
    Cancer Res. 2001 Aug 1;61(15):5723-6 PMID: 11479206
  28. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
    Cancer Lett. 2009 Mar 18;275(2):234-9 PMID: 19046801
  29. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Br J Cancer. 2006 Nov 20;95(10):1390-5 PMID: 17060940
  30. The first 30 years of p53: growing ever more complex.
    Nat Rev Cancer. 2009 Oct;9(10):749-58 PMID: 19776744
  31. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer.
    J Urol. 2009 Jan;181(1):363-71 PMID: 19010497
  32. Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico.
    Gynecol Oncol. 2010 May;117(2):291-6 PMID: 20199804
  33. Flow cytometric analysis of circulating microparticles in plasma.
    Cytometry A. 2010 Jun;77(6):502-14 PMID: 20235276
  34. Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR.
    Cancer Genomics Proteomics. 2008 Mar-Apr;5(2):94-104 PMID: 18460738
  35. Medicine. Keeping tabs on tumor DNA.
    Science. 2010 Feb 26;327(5969):1074 PMID: 20185705
  36. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.
    Clin Chem. 2008 Aug;54(8):e1-e10 PMID: 18606634
  37. A novel and universal method for microRNA RT-qPCR data normalization.
    Genome Biol. 2009;10(6):R64 PMID: 19531210
  38. Shedding microvesicles: artefacts no more.
    Trends Cell Biol. 2009 Feb;19(2):43-51 PMID: 19144520
  39. Reduced plasma RNA integrity in nasopharyngeal carcinoma patients.
    Clin Cancer Res. 2006 Apr 15;12(8):2512-6 PMID: 16638860
  40. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2010 Sep;136(9):1341-7 PMID: 20155428
  41. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
    Breast Cancer Res. 2009;11(5):R71 PMID: 19772563
  42. Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas.
    Leuk Lymphoma. 2010 Jun;51(6):1020-7 PMID: 20470219
  43. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications.
    Carcinogenesis. 2003 Dec;24(12):1897-901 PMID: 12970072
  44. Methylation profile of circulating plasma DNA in patients with pancreatic cancer.
    J Surg Oncol. 2009 Feb 1;99(2):119-22 PMID: 19065635
  45. Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA.
    Clin Exp Immunol. 1984 Apr;56(1):185-92 PMID: 6609032
  46. Circulating nucleic acids (CNAs) and cancer--a survey.
    Biochim Biophys Acta. 2007 Jan;1775(1):181-232 PMID: 17137717
  47. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
    Int J Cancer. 2008 Feb 15;122(4):952-6 PMID: 17960617
  48. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma.
    Biomarkers. 2009 Nov;14(7):529-38 PMID: 19863192
  49. Prediction of breast tumor progression by integrity of free circulating DNA in serum.
    J Clin Oncol. 2006 Sep 10;24(26):4270-6 PMID: 16963729
  50. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection.
    Liver Int. 2008 Mar;28(3):393-401 PMID: 18028321
  51. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer.
    Clin Cancer Res. 2002 Jan;8(1):35-40 PMID: 11801538
  52. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.
    Clin Chem. 2009 Jul;55(7):1337-46 PMID: 19406918
  53. EGFR antagonists in cancer treatment.
    N Engl J Med. 2008 Mar 13;358(11):1160-74 PMID: 18337605
  54. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
    Mol Cancer. 2009 Nov 17;8:105 PMID: 19922604
  55. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
    J Natl Cancer Inst. 2004 Jan 21;96(2):152-6 PMID: 14734706
  56. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.
    Clin Biochem. 2006 Apr;39(4):344-8 PMID: 16527261
  57. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
    Cancer Res. 2006 Jun 15;66(12):6111-7 PMID: 16778184
  58. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
    N Engl J Med. 2004 Jun 10;350(24):2461-70 PMID: 15190138
  59. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.
    World J Surg. 2004 Jul;28(7):721-6 PMID: 15185002
  60. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients.
    Cancer Res. 1999 Apr 1;59(7):1567-71 PMID: 10197630
  61. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients.
    Clin Biochem. 2010 Mar;43(4-5):373-9 PMID: 19879256
  62. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
    Ann N Y Acad Sci. 2004 Jun;1022:76-80 PMID: 15251943
  63. Genomic DNA methylation: the mark and its mediators.
    Trends Biochem Sci. 2006 Feb;31(2):89-97 PMID: 16403636
  64. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia.
    Br J Haematol. 1994 Apr;86(4):774-9 PMID: 7918071
  65. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients.
    Blood. 2004 Jul 1;104(1):243-9 PMID: 15031209
  66. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease.
    Clin Cancer Res. 2005 Feb 15;11(4):1394-9 PMID: 15746038
  67. Histone deacetylase inhibitors in cancer therapy.
    J Clin Oncol. 2009 Nov 10;27(32):5459-68 PMID: 19826124
  68. Free circulating mRNA in plasma from breast cancer patients and clinical outcome.
    Cancer Lett. 2008 May 18;263(2):312-20 PMID: 18280643
  69. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
    Br J Cancer. 2006 May 22;94(10):1492-5 PMID: 16641902
  70. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer.
    DNA Cell Biol. 2008 Aug;27(8):415-21 PMID: 18694299
  71. Global cancer statistics.
    CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 PMID: 21296855
  72. Clinical relevance of circulating nucleosomes in cancer.
    Ann N Y Acad Sci. 2008 Aug;1137:180-9 PMID: 18837945
  73. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker.
    BJU Int. 2009 Jul;104(1):48-52 PMID: 19154496
  74. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients.
    Ann N Y Acad Sci. 2008 Aug;1137:222-5 PMID: 18837951
  75. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
    Br J Cancer. 2009 Nov 17;101(10):1724-30 PMID: 19861964
  76. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
    Nat Genet. 1999 Jan;21(1):103-7 PMID: 9916800
  77. Active Alu retrotransposons in the human genome.
    Genome Res. 2008 Dec;18(12):1875-83 PMID: 18836035
  78. Methylation of endogenous human retroelements in health and disease.
    Curr Top Microbiol Immunol. 2006;310:211-50 PMID: 16909913
  79. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients.
    Ann N Y Acad Sci. 2006 Sep;1075:197-203 PMID: 17108212
  80. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.
    Eur J Med Res. 2010;15:277-86 PMID: 20696638
  81. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer.
    Clin Chem. 2011 Jan;57(1):84-91 PMID: 21036945
  82. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer.
    Ann N Y Acad Sci. 2008 Aug;1137:171-4 PMID: 18837943
  83. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
    Clin Cancer Res. 2007 Apr 1;13(7):2068-74 PMID: 17404088
  84. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma.
    Clin Chim Acta. 2007 Apr;379(1-2):127-33 PMID: 17303099
  85. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.
    Clin Cancer Res. 2009 Feb 1;15(3):1032-8 PMID: 19188176
  86. Extracellular DNA in breast cancer: Cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and nonmalignant tumors.
    Ann N Y Acad Sci. 2004 Jun;1022:217-20 PMID: 15251963
  87. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy.
    Med Res Rev. 2008 Sep;28(5):645-87 PMID: 18271058
  88. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment.
    Clin Chem. 2009 Aug;55(8):1471-83 PMID: 19520761
  89. Nucleosomes in serum of patients with benign and malignant diseases.
    Int J Cancer. 2001 Mar 20;95(2):114-20 PMID: 11241322
  90. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer.
    Ann Surg. 2010 Feb;251(2):275-80 PMID: 20010083
  91. Biomarkers of apoptosis.
    Br J Cancer. 2008 Sep 16;99(6):841-6 PMID: 19238626
  92. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2008 May;141(5):672-5 PMID: 18318758
  93. Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients.
    Clin Cancer Res. 2008 Jul 1;14(13):4141-5 PMID: 18593992
  94. The methyl-CpG binding domain and the evolving role of DNA methylation in animals.
    Trends Genet. 2003 May;19(5):269-77 PMID: 12711219
  95. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.
    Cancer Res. 2001 Feb 15;61(4):1659-65 PMID: 11245480
  96. Quantitative analysis of circulating mitochondrial DNA in plasma.
    Clin Chem. 2003 May;49(5):719-26 PMID: 12709361
  97. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.
    J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9 PMID: 12419787
  98. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa.
    Int J Cancer. 2004 Jun 20;110(3):374-9 PMID: 15095302
  99. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer.
    Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):662-7 PMID: 16150257
  100. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
    Clin Chim Acta. 2010 Sep 6;411(17-18):1319-24 PMID: 20576522
  101. Amount of DNA in plasma and cancer risk: a prospective study.
    Int J Cancer. 2004 Sep 20;111(5):746-9 PMID: 15252845
  102. Circulating nucleic acids in plasma and serum: recent developments.
    Ann N Y Acad Sci. 2006 Sep;1075:1-9 PMID: 17108186
  103. Human papillomavirus DNA in plasma of patients with cervical cancer.
    BMC Cancer. 2001;1:2 PMID: 11244579
  104. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
    Cancer. 2010 Apr 15;116(8):1918-25 PMID: 20166213
  105. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis.
    Cancer. 2010 Apr 1;116(7):1674-80 PMID: 20143430
  106. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2005 Feb 24;352(8):786-92 PMID: 15728811
  107. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases.
    Int J Biol Markers. 2006 Oct-Dec;21(4):223-8 PMID: 17177160
  108. DNA-based detection of prostate cancer in blood, urine, and ejaculates.
    Ann N Y Acad Sci. 2001 Sep;945:51-8 PMID: 11708494
  109. Soluble normal and mutated DNA sequences from single-copy genes in human blood.
    Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71 PMID: 8118388
  110. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity.
    Cancer Lett. 2008 Jun 18;264(2):274-80 PMID: 18329789
  111. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients.
    Clin Cancer Res. 2000 Sep;6(9):3516-21 PMID: 10999738
  112. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer.
    Eur Urol. 2002 Dec;42(6):622-8; discussion 628-30 PMID: 12477660
  113. Nuclear Acids In Human Blood Plasma.
    C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3 PMID: 18875018
  114. DNA methylation in serum and tumors of cervical cancer patients.
    Clin Cancer Res. 2004 Jan 15;10(2):565-71 PMID: 14760078
  115. Suitable reference genes for relative quantification of miRNA expression in prostate cancer.
    Exp Mol Med. 2010 Nov 30;42(11):749-58 PMID: 20890088
  116. Role of active cell death (apoptosis) in multi-stage carcinogenesis.
    Toxicol Lett. 1995 Dec;82-83:143-8 PMID: 8597042
  117. Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool.
    Clin Chem. 2004 Nov;50(11):2171-3 PMID: 15502091
  118. Cell-surface-bound nucleic acids: Free and cell-surface-bound nucleic acids in blood of healthy donors and breast cancer patients.
    Ann N Y Acad Sci. 2004 Jun;1022:221-7 PMID: 15251964
  119. MicroRNA expression profiles classify human cancers.
    Nature. 2005 Jun 9;435(7043):834-8 PMID: 15944708
  120. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
    Clin Cancer Res. 2005 Jun 1;11(11):4037-43 PMID: 15930338
  121. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer.
    Ann N Y Acad Sci. 2008 Aug;1137:190-6 PMID: 18837946
  122. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
    Breast Cancer Res. 2010;12(6):R90 PMID: 21047409
  123. MicroRNAs: target recognition and regulatory functions.
    Cell. 2009 Jan 23;136(2):215-33 PMID: 19167326
  124. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas.
    Clin Cancer Res. 2004 Mar 1;10(5):1726-32 PMID: 15014025
  125. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
    Int J Cancer. 2011 Jun 1;128(11):2572-80 PMID: 20715113
  126. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
    J Clin Oncol. 2006 Dec 1;24(34):5414-8 PMID: 17135642
  127. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):421-6 PMID: 17255261
  128. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
    BJU Int. 2008 Aug 5;102(5):628-32 PMID: 18410441
  129. Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression.
    BMC Cancer. 2011 Jan 06;11:4 PMID: 21211028
  130. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis.
    Cancer Res. 2000 Feb 1;60(3):707-11 PMID: 10676657
  131. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay.
    PLoS One. 2008;3(11):e3759 PMID: 19018278
  132. Methylation status of the fragile histidine triad and E-cadherin genes in plasma of cervical cancer patients.
    Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1862-7 PMID: 17009983
  133. Microsatellite alterations in serum DNA of head and neck cancer patients.
    Nat Med. 1996 Sep;2(9):1035-7 PMID: 8782464
  134. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer.
    BJU Int. 2006 Sep;98(3):544-8 PMID: 16925751
  135. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients.
    Cancer Res. 2003 Apr 15;63(8):1884-7 PMID: 12702578
  136. CIRCULATING DNA AS A POSSIBLE FACTOR IN ONCOGENESIS.
    Science. 1965 Apr 16;148(3668):374-6 PMID: 14261529
  137. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.
    Cancer Res. 1999 Mar 15;59(6):1188-91 PMID: 10096545
  138. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators.
    Int J Cancer. 2008 Jan 1;122(1):138-43 PMID: 17764114
  139. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.
    Gut. 2009 Oct;58(10):1375-81 PMID: 19201770
  140. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.
    Cancer Res. 2001 Jun 15;61(12):4675-8 PMID: 11406535
  141. MicroRNAs as Novel Biomarkers for Breast Cancer.
    J Oncol. 2009;2009:950201 PMID: 19639033
  142. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.
    Clin Chem. 2006 Jun;52(6):1062-9 PMID: 16723681
  143. Molecular detection of genetic alterations in the serum of colorectal cancer patients.
    Cancer Res. 1998 Apr 1;58(7):1405-7 PMID: 9537240
  144. Circulating thyroglobulin mRNA does not predict early and midterm recurrences in patients undergoing thyroidectomy for cancer.
    Am J Surg. 2008 Sep;196(3):326-32 PMID: 18614150
  145. Microsatellite analysis of serum DNA in patients with head and neck cancer.
    Int J Cancer. 2004 Aug 10;111(1):96-100 PMID: 15185349
  146. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up.
    Gut. 2003 Jan;52(1):101-8 PMID: 12477769
  147. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2010 Feb 15;16(4):1324-30 PMID: 20145159
  148. Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse.
    Int J Cancer. 2004 Jul 20;110(6):914-20 PMID: 15170676
  149. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.
    J Clin Oncol. 1999 Feb;17(2):578-84 PMID: 10080602
  150. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
    J Clin Oncol. 2005 Dec 20;23(36):9351-8 PMID: 16361635
  151. Causes and consequences of microRNA dysregulation in cancer.
    Nat Rev Genet. 2009 Oct;10(10):704-14 PMID: 19763153
  152. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer.
    PLoS Genet. 2010 Apr 22;6(4):e1000917 PMID: 20421991
  153. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells.
    Cancer Res. 2010 Jan 15;70(2):560-7 PMID: 20068178
  154. Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions.
    Clin Cancer Res. 2007 Oct 1;13(19):5805-9 PMID: 17908972
  155. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.
    Clin Cancer Res. 2002 Jan;8(1):29-34 PMID: 11801537
  156. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients.
    Cancer Lett. 2002 Dec 15;188(1-2):109-14 PMID: 12406555
  157. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.
    Cancer Res. 2005 Feb 15;65(4):1141-5 PMID: 15734995
  158. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.
    J Clin Oncol. 2010 Apr 1;28(10):1721-6 PMID: 20194856
  159. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer.
    Ann N Y Acad Sci. 2008 Aug;1137:175-9 PMID: 18837944
  160. Apoptosis and nucleosomes.
    Lupus. 2002;11(12):787-9 PMID: 12529041
  161. Circulating microRNAs as stable blood-based markers for cancer detection.
    Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 PMID: 18663219
  162. Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging.
    Ann N Y Acad Sci. 2000 Apr;906:99-101 PMID: 10818603
  163. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells.
    Immunology. 2005 May;115(1):55-62 PMID: 15819697
  164. Circulating mutant DNA to assess tumor dynamics.
    Nat Med. 2008 Sep;14(9):985-90 PMID: 18670422
  165. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
    J Clin Oncol. 2005 Dec 20;23(36):9105-12 PMID: 16361617
  166. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.
    Cancer Res. 2000 Dec 15;60(24):6878-81 PMID: 11156384
  167. Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression.
    Melanoma Res. 2010 Aug;20(4):303-10 PMID: 20442676
  168. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
    Br J Cancer. 1997;76(10):1293-9 PMID: 9374374
  169. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.
    Clin Chem. 2008 Sep;54(9):1528-36 PMID: 18653827
  170. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours.
    J Pathol. 2002 Jan;196(1):1-7 PMID: 11748635
  171. Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
    Cancer Lett. 2007 Sep 8;254(2):265-73 PMID: 17449174
  172. Quantitative analysis of plasma HBV DNA for early evaluation of the response to transcatheter arterial embolization for HBV-related hepatocellular carcinoma.
    World J Gastroenterol. 2005 Oct 21;11(39):6193-6 PMID: 16273649
  173. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Clin Cancer Res. 2002 Dec;8(12):3782-7 PMID: 12473590
  174. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
    Prostate. 2008 Jan 1;68(1):42-9 PMID: 18004747
  175. Circulating tumour cells in cancer patients: challenges and perspectives.
    Trends Mol Med. 2010 Sep;16(9):398-406 PMID: 20667783
  176. Detection, clinical relevance and specific biological properties of disseminating tumour cells.
    Nat Rev Cancer. 2008 May;8(5):329-40 PMID: 18404148
  177. The origin and mechanism of circulating DNA.
    Ann N Y Acad Sci. 2000 Apr;906:161-8 PMID: 10818614
  178. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
    Int J Cancer. 2007 Apr 1;120(7):1465-71 PMID: 17205532
  179. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome.
    Cancer Res. 2004 Jun 15;64(12):4085-8 PMID: 15205316
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc3066
Published
2011-06-00
Epub
2011-00-12
Pages
426-37
Language
English
Region
England
NLM ID
101124168
Subset
IM
Grants
NCI NIH HHS · CA12582 · United States
NCI NIH HHS · R33 PO1 CA29605 · United States
External Links
PubMed source DOI: 10.1038/nrc3066 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2